Scarica l'app Stockscreener
53.31
0.60%
0.32
Precedente Chiudi:
$52.99
Aprire:
$53.05
Volume 24 ore:
1.58M
Relative Volume:
0.61
Capitalizzazione di mercato:
$10.24B
Reddito:
$2.95B
Utile/perdita netta:
$523.88M
Rapporto P/E:
19.82
EPS:
2.69
Flusso di cassa netto:
$620.18M
1 W Prestazione:
-0.17%
1M Prestazione:
-3.63%
6M Prestazione:
-6.93%
1 anno Prestazione:
-19.54%
Intervallo 1D:
$52.58
$53.33
Intervallo di 1 settimana:
$52.55
$54.33
Portata 52W:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Nome
Biomarin Pharmaceutical Inc
Settore
Industria
Telefono
(415) 506-6700
Indirizzo
105 DIGITAL DRIVE, NOVATO, CA
Confronta BMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.31 | 10.18B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-11-06 | Downgrade | Stifel | Buy → Hold |
| 2025-09-08 | Iniziato | H.C. Wainwright | Neutral |
| 2025-09-03 | Iniziato | Raymond James | Outperform |
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-24 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-30 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-20 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Iniziato | Evercore ISI | Outperform |
| 2023-11-15 | Iniziato | Wells Fargo | Overweight |
| 2023-10-23 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Iniziato | Raymond James | Mkt Perform |
| 2023-09-18 | Iniziato | UBS | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-07-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2023-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Iniziato | Citigroup | Neutral |
| 2023-01-30 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2022-10-31 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2022-04-25 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-09-09 | Aggiornamento | Stifel | Hold → Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-04 | Ripresa | Guggenheim | Buy |
| 2021-03-01 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Downgrade | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Downgrade | Stifel | Buy → Hold |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Reiterato | Citigroup | Buy |
| 2020-01-28 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-27 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-01-24 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-04-09 | Ripresa | Raymond James | Outperform |
| 2019-01-02 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Reiterato | Stifel | Buy |
| 2018-08-03 | Reiterato | Stifel | Buy |
Mostra tutto
Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie
BioMarin Pharmaceutical Inc. $BMRN Holdings Lowered by Hudson Bay Capital Management LP - MarketBeat
Bellevue Group AG Lowers Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Boone Capital Management LLC Has $24.60 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
AQR Capital Management LLC Acquires 2,654,768 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Camber Capital Management LP Has $32.98 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
How Restructuring-Driven Margin Gains And Higher Guidance At BioMarin (BMRN) Have Changed Its Investment Story - Sahm
Leerink cuts BioMarin Pharmaceutical Inc. (BMRN) price target to $60, citing valuation and competitive challenges - MSN
Leerink Cuts BioMarin Pharmaceutical Inc. (BMRN) Price Target to $60, Citing Valuation and Competitive Challenges - Yahoo Finance
California Public Employees Retirement System Sells 102,629 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Inozyme Pharma Acquisition Finalized by BioMarin - Ad-hoc-news.de
BioMarin Pharmaceutical Inc. (BMRN) Outlook Lowered By Leerink - Finviz
BioMarin Pharmaceutical Inc. (BMRN) outlook lowered by Leerink - MSN
Arrowstreet Capital Limited Partnership Raises Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
August 2026 Options Now Available For BioMarin Pharmaceutical (BMRN) - Nasdaq
Jump Financial LLC Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Technical Reactions to BMRN Trends in Macro Strategies - news.stocktradersdaily.com
BioMarin Pharmaceutical Inc. (BMRN): A bull case theory - MSN
Schroder Investment Management Group Trims Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
What margin trends mean for BioMarin Pharmaceutical Inc. stockJuly 2025 Highlights & Free Risk Controlled Daily Trade Plans - Newser
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Dodge & Cox - MarketBeat
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyJuly 2025 Catalysts & Low Risk Growth Stock Ideas - Newser
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts - Yahoo! Finance Canada
BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory - Finviz
BioMarin Loses Hormone Patent In Europe - Law360
BioMarin Pharmaceutical (NASDAQ:BMRN) Lowered to "Market Perform" Rating by Leerink Partners - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Cut to "Hold" at Leerink Partnrs - MarketBeat
Is BioMarin Pharmaceutical Inc. stock undervalued vs historical averagesJuly 2025 Chart Watch & Advanced Swing Trade Entry Alerts - Newser
Can BioMarin Pharmaceutical Inc. (BM8) stock withstand sector downturns2025 Key Lessons & Technical Pattern Based Signals - Newser
Mackenzie Financial Corp Grows Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
2,043,879 Shares in BioMarin Pharmaceutical Inc. $BMRN Acquired by Norges Bank - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform By Investing.com - Investing.com South Africa
Uber To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
This Wayfair Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
BMRN Experiences Downgrade and Price Target Cut by Leerink Partn - GuruFocus
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Sio Capital Management LLC - MarketBeat
Leerink Partners downgrades BioMarin stock rating to Market Perform - Investing.com
Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 - marketscreener.com
Hsbc Holdings PLC Boosts Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Korea Investment CORP Raises Stock Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Skandinaviska Enskilda Banken AB publ - MarketBeat
Edgestream Partners L.P. Has $7.12 Million Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pharma giant BioMarin announces €60m investment in Cork facility - MSN
Quadrature Capital Ltd Purchases New Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Pullback Watch: Is BioMarin Pharmaceutical Inc. stock oversold or undervaluedQuarterly Market Review & Stock Market Timing Techniques - BỘ NỘI VỤ
Icon Advisers Inc. Co. Has $973,000 Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Charles Schwab Investment Management Inc. Grows Stake in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Vinva Investment Management Ltd Has $1.72 Million Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Thornburg Investment Management Inc. Sells 7,417 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Prudential Financial Inc. Boosts Stock Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Bought by Rhumbline Advisers - MarketBeat
Biomarin Pharmaceutical Inc Azioni (BMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):